XCUR Share Price | Exicure, Inc. Stock Analysis & Recommendation

Q: How big is Exicure, Inc.?

Market Cap: As of Jun 18, Exicure, Inc. has a market capitalization of 52.56 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Exicure, Inc. reported net sales of 0.50 million and a net profit of -9.70 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.77 million and total assets of 15.06 million.

Q: What does Exicure, Inc. do?

Overview:Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immuno-oncology, genetic disorders, and other indications based on its Spherical Nucleic Acid (SNA) technology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -7 Million (Quarterly Results - Dec 2024) Market cap: USD 52.56 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.74 Return on Equity: -41.72% Price to Book: 7.76 Contact Details:Address: 2430 N. HALSTED ST., CHICAGO IL : 60614 Tel: ['1 847 6731700', '1 781 2353060'] Fax: 1 847 5566411 Website: http://www.exicuretx.com/

Q: Is Exicure, Inc. overvalued or undervalued?

As of 9 February 2024, Exicure, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its P/B ratio of 10.08 and negative metrics such as an EV to EBITDA of -13.68 and an ROE of -41.72%. When compared to peers, Exicure's valuation metrics are less favorable; for instance, Benitec Biopharma, Inc. has an EV to EBITDA of -10.1454, and Monopar Therapeutics, Inc. stands at -8.7189. The stark contrast in performance is further underscored by Exicure's poor stock performance, with a year-to-date decline of 52.45% compared to a modest 2.44% gain in the S&P 500. Overall, the financial ratios and peer comparisons suggest that Exicure, Inc. is significantly overvalued in the current market.

Q: Is Exicure, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Exicure, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, both the Bollinger Bands and KST are bearish on the weekly timeframe. In terms of multi-period returns, Exicure has significantly underperformed the S&P 500, with a year-to-date return of -71.62% compared to the S&P's 12.22%, and a 5-year return of -98.74% against the S&P's 96.61%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

638

Shareholding (Dec 2025)

FII

0.89%

Held by 4 FIIs

DII

97.23%

Held by 1 DIIs

Promoter

0.89%

How big is Exicure, Inc.?

22-Jun-2025

As of Jun 18, Exicure, Inc. has a market capitalization of 52.56 million, with net sales of 0.50 million and a net profit of -9.70 million over the last four quarters. The company reported shareholder's funds of 6.77 million and total assets of 15.06 million as of Dec 24.

View full answer

What does Exicure, Inc. do?

22-Jun-2025

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics using its Spherical Nucleic Acid technology for immuno-oncology and genetic disorders, with a market cap of $52.56 million and a recent net profit of -$7 million.

View full answer

Who are in the management team of Exicure, Inc.?

22-Jun-2025

As of March 2022, the management team of Exicure, Inc. includes Timothy Walbert (Independent Chairman), Dr. David Giljohann (CEO and Director), Dr. Chad Mirkin, James Sulat, Dr. Jeffrey Cleland, Bosun Hau, and Helen Kim (all Directors). They oversee the company's strategic direction and operations.

View full answer

Is Exicure, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Exicure, Inc. is significantly overvalued with a P/B ratio of 10.08 and negative financial metrics, leading to a downgrade in its valuation grade and a year-to-date stock decline of 52.45%, contrasting sharply with its peers and the S&P 500.

View full answer

Is Exicure, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Exicure, Inc. is in a bearish trend with weak strength, indicated by negative MACD, RSI, and moving averages, and has underperformed the S&P 500 with a year-to-date return of -71.62% compared to the S&P's 12.22%.

View full answer

Compare Exicure, Inc. with Similar Stocks

Kintara Therapeutics, Inc.Applied Molecular Transport, Inc.Benitec Biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 29 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.59

Return on Equity

-131.07%

Price to Book

4.22

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.38%

6 Months

-14.9%

1 Year

-70.39%

2 Years

40.27%

3 Years

212.04%

4 Years

-81.87%

5 Years

-98.76%

Exicure, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

9.81%

EBIT to Interest (avg)

-16.66

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.86

Sales to Capital Employed (avg)

1.20

Tax Ratio

0.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.91%

ROCE (avg)

94.11%

ROE (avg)

105.78%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.22

EV to EBIT

-2.70

EV to EBITDA

-2.86

EV to Capital Employed

8.88

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-328.91%

ROE (Latest)

-131.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (0.99%)

Foreign Institutions

Held by 4 Foreign Institutions (0.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.83% vs 7.69% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-2.30",
          "chgp": "8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "-0.10",
          "chgp": "-900.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.90",
          "val2": "-2.40",
          "chgp": "-20.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 49.48% vs 42.60% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.70",
          "val2": "-4.10",
          "chgp": "-136.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.80",
          "val2": "-6.90",
          "chgp": "169.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.90",
          "val2": "-9.70",
          "chgp": "49.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-9,898.00%",
          "chgp": "989.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.10

-2.30

8.70%

Interest

0.00

Exceptional Items

-1.00

-0.10

-900.00%

Consolidate Net Profit

-2.90

-2.40

-20.83%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.83% vs 7.69% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

0.50

-100.00%

Operating Profit (PBDIT) excl Other Income

-9.70

-4.10

-136.59%

Interest

0.00

Exceptional Items

4.80

-6.90

169.57%

Consolidate Net Profit

-4.90

-9.70

49.48%

Operating Profit Margin (Excl OI)

0.00%

-9,898.00%

989.80%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -100.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 49.48% vs 42.60% in Dec 2024

All Annual Results

Company CV

About Exicure, Inc.

Exicure, Inc.

Pharmaceuticals & Biotechnology

Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).

Company Coordinates

Company Details

2430 N. HALSTED ST. , CHICAGO IL : 60614

Tel: 1 847 67317001 781 2353060

http://www.exicuretx.com/

Registrar Details